NASDAQ · Health care

Mesoblast Ltd (MESO)

Mesoblast Ltd reported revenue of $17.2M in fiscal 2025, up 191.4% from a year earlier. It posted a net loss of $102.1M. In fiscal 2025 capital spending exceeded operating cash flow by $50.6M. At June 30, 2025 it held $161.6M in cash against $121.9M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on August 27, 2026.

Watch MESO in 60 seconds

Price

$15.12

-2.33% on the day · September 25, 2026

52-week range $13.05 to $21.50

Market cap

$2B

Revenue (FY2025)

$17.2M

+191.4% year on year

Net margin

-593.9%

What Mesoblast Ltd does

Mesoblast Ltd is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MESO.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$17.2M	n/a	-$102.1M	-$0.08	-$50.6M
2024	$5.9M	n/a	-$88M	-$0.09	-$48.7M
2023	$7.5M	n/a	-$81.9M	-$0.11	-$63.5M
2022	$10.2M	n/a	-$91.3M	-$0.13	n/a
2021	$7.4M	n/a	-$98.8M	-$0.16	n/a
2020	$32.2M	n/a	-$77.9M	-$0.14	n/a

Full financial statements: income, balance sheet and cash flow

Where MESO ranks in Health care

Revenue$17.2M

#484 of 742 in Health care · Bottom 35%

Revenue growth+191.4%

#33 of 529 in Health care · Top 6%

Net margin-593.9%

#520 of 541 in Health care · Bottom 4%

Free cash flow margin-294.4%

#451 of 488 in Health care · Bottom 8%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Mesoblast Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 24, 2026
Foreign issuer update 6-K
August 27, 2026
Foreign issuer update 6-K
August 27, 2026
Annual report (foreign issuer) 20-F · period to June 30, 2026
August 25, 2026
Foreign issuer update 6-K
August 24, 2026
Foreign issuer update 6-K
August 18, 2026
Foreign issuer update 6-K
July 30, 2026
Foreign issuer update 6-K
July 21, 2026
Foreign issuer update 6-K
July 15, 2026
Foreign issuer update 6-K
July 14, 2026
Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 9, 2026. Insider transactions on SEC

Insider trades

What the people running Mesoblast Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
April 10, 2026	George GregoryDirector, 10% owner	Boughtindirect	2,324,072	$1.48	$3.4M	Form 4
April 10, 2026	George GregoryDirector, 10% owner	Boughtindirect	2,324,072	$1.48	$3.4M	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	886,890	$1.43	$1.3M	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	105,000	$1.46	$153.3K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	500,000	$1.44	$720K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	10,000	$1.44	$14.4K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	4,760	$1.44	$6.9K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	20,000	$1.43	$28.6K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	10,000	$1.43	$14.3K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	5,240	$1.43	$7.5K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	10,000	$1.43	$14.3K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	5,000	$1.43	$7.2K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	10,000	$1.43	$14.3K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	10,000	$1.43	$14.3K	Form 4
April 9, 2026	George GregoryDirector, 10% owner	Boughtindirect	10,000	$1.41	$14.1K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns MESO

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
George, Gregory13G, passive with 3 related filers	22.36%	288,522,256	March 11, 2026
Gregory George13G, passive with 3 related filers	18.88%	215,549,921	December 16, 2024
Gueck William J.13G, passive	5%	64,521,900	September 16, 2025

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 8,324,072 shares in total, about $125.9M at the last price.

Holder	Shares	As of
George GregoryDirector, 10% owner	8,324,0728,324,072 held indirectly	April 10, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about MESO

What does Mesoblast Ltd do?

Mesoblast Ltd is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MESO.

Is Mesoblast Ltd profitable?

No. In fiscal 2025 it reported a net loss of $102.1M on revenue of $17.2M.

How much revenue does Mesoblast Ltd make?

In fiscal 2025 Mesoblast Ltd reported revenue of $17.2M. That is 191.4% more than a year earlier.

When did Mesoblast Ltd last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on August 27, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the foreign issuer update from September 24, 2026.

Similar companies

AMGN

Amgen Inc

GILD

Gilead Sciences, Inc.

Neurocrine Biosciences Inc

EXEL

Exelixis, Inc.

Compare MESO with

Compare MESO with any company

Follow MESO

Get an email when Mesoblast Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow MESO: get an email when it files

Where the numbers come from

Financial figures are the values Mesoblast Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.